Skip to main content
. 2022 Sep 1;28(21):4714–4723. doi: 10.1158/1078-0432.CCR-22-0749

Figure 2.

Figure 2. Survival analysis according to (A and B) Sig3-status using panel data (median survival: 5.6 vs. 7.7 months in Sig3− and Sig3+ samples, respectively) and WES (median survival: 5.0 vs. 8.5 in Sig3− and Sig3+ samples respectively), C, GIS (median survival: 5.6 months vs. 7.0 months in GIS+ and GIS− samples, respectively), D, BRCA1/2mut or WT, (median survival: 5.5 months vs. 7.3 months in WT vs. BRCA1/2mut samples, respectively). Cox multivariate regression including (E) Sig3-status or (F) GIS. Age, ECOG, and stage as covariates did not have significant HR and were not included as covariates. “Prior lines” refers to the number of previous lines of therapy in the metastatic setting.

Survival analysis according to (A and B) Sig3 status using panel data (median survival: 5.6 vs. 7.7 months in Sig3− and Sig3+ samples, respectively) and WES (median survival: 5.0 vs. 8.5 in Sig3− and Sig3+ samples respectively); C, GIS (median survival: 5.6 months vs. 7.0 months in GIS+ and GIS− samples, respectively); D,BRCA1/2mut or WT (median survival: 5.5 months vs. 7.3 months in WT vs. BRCA1/2mut samples, respectively). Cox multivariate regression including (E) Sig3 status or (F) GIS. Age, ECOG, and stage as covariates did not have significant HR and were not included as covariates. “Prior lines” refers to the number of previous lines of therapy in the metastatic setting.